Core Points - InMed Pharmaceuticals has appointed CBIZ as its new auditor following the resignation of Marcum LLP due to CBIZ's acquisition of Marcum's attest business, effective June 12, 2025 [1][2] - The resignation of Marcum was not due to any disagreements regarding InMed's financial statements, and previous audit reports did not contain adverse opinions [2] - A special meeting of shareholders was held but no business was conducted due to lack of quorum, resulting in no vote on the proposed issuance of 20% or more of the Company's common shares [3] - InMed has amended its Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing for a temporary suspension of the use of its existing registration statement during a "Black Out Period" [4][5] - During any Black Out Period, Yorkville is prohibited from selling shares under the registration statement, but may sell through other legal exemptions [5][6] Company Overview - InMed Pharmaceuticals focuses on developing proprietary small molecule drug candidates targeting diseases with high unmet medical needs, including Alzheimer's and dermatological conditions [8]